MedTrace Logo

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

NCT04939662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-01-02

No results posted yet for this study

Summary

This study is a single arm, multi-centre phase II study of olaparib and bevacizumab combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line (systemic) therapy.

Subjects will receive olaparib and bevacizumab combination therapy. The arm is composed of 28 subjects.

Olaparib 300 mg bid per os every 12 hours administered each cycle day and bevacizumab 15 mg/kg via IV administered on Day 1 of every cycle for every 3 weeks. One cycle consists of 21 days.

Conditions

Interventions

DRUG

Olaparib+Bevacizumab to SCLC patients

Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days. The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • Se-Hoon Lee

    lead OTHER

Principal Investigators

  • Se-Hoon Lee, Professor · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2023-10-27
Completion
2023-10-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939662 on ClinicalTrials.gov